Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer

Study:

A Limited Access Trial Using Amifostine for Protection Against Cisplatin and 3-Hour Paclitaxel-Induced Neurotoxicity

Rationale:

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.

Purpose:

Phase II trial to study the effectiveness of amifostine in reducing the risk of side effects caused by cisplatin and paclitaxel in treating women who have ovarian, peritoneal, cervical, fallopian tube, uterine, or endometrial cancer.

Study Status: Terminated

Recruiting:
n/a

Condition Intervention Phase
Cervical Cancer
Endometrial Cancer
Fallopian Tube Cancer
Neurotoxicity
Ovarian Cancer
Primary Peritoneal Cavity Cancer
Sarcoma
Drug: amifostine trihydrate
Drug: cisplatin
Drug: paclitaxel
Phase 2

Verified by Gynecologic Oncology Group May, 2006

Sponsored by: Gynecologic Oncology Group
Information provided by: Gynecologic Oncology Group
ClinicalTrials.gov identifier: NCT00003624

Study Type: Interventional

Study Design: Primary Purpose: Supportive Care

Cleveland Clinic Cancer Center
Cleveland, Ohio 44195
United States

David H. Moore, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site